Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m. Marinus is a commercial-stage pharmaceutical company ...

Immedica, through a wholly owned, direct subsidiary, will initiate a tender offer to acquire all shares of Marinus for a cash purchase price of $0.55 per share, representing a premium of 48% based ...